Can you provide the average price target for BIOVENTUS INC - A stock?
8 analysts have analysed BVS and the average price target is 14.79 USD. This implies a price increase of 71.18% is expected in the next year compared to the current price of 8.64.
NASDAQ:BVS • US09075A1088
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOVENTUS INC - A (BVS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-06 | Barrington Research | Maintains | Outperform -> Outperform |
| 2026-03-06 | Craig-Hallum | Maintains | Buy -> Buy |
| 2026-02-09 | Barrington Research | Initiate | Outperform |
| 2025-07-07 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-17 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-12-17 | JP Morgan | Upgrade | Underweight -> Neutral |
| 2024-11-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-09-27 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-08-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-07 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-05-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-13 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-12-07 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2023-04-03 | Craig-Hallum | Maintains | Hold |
| 2022-11-30 | Goldman Sachs | Maintains | Neutral |
| 2022-11-22 | Craig-Hallum | Downgrade | Buy -> Hold |
| 2022-11-10 | Morgan Stanley | Maintains | Overweight |
| 2022-11-09 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2022-11-09 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-10-11 | Morgan Stanley | Maintains | Overweight |
| 2022-09-07 | Goldman Sachs | Maintains | Neutral |
| 2022-08-12 | Morgan Stanley | Maintains | Overweight |
| 2022-05-12 | Morgan Stanley | Maintains | Overweight |
| 2022-03-11 | Morgan Stanley | Maintains | Overweight |
| 2021-11-15 | Morgan Stanley | Reiterate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 512.345M 0.05% | 573.28M 11.89% | 568.087M -0.91% | 610.31M 7.43% | 650.65M 6.61% | 694.1M 6.68% | 737.07M 6.19% | 792.93M 7.58% | |
| EBITDA YoY % growth | 58.672M 397.22% | 70.957M 20.94% | 103.302M 45.58% | 119.45M 15.63% | 133.79M 12.01% | N/A | 156.31M | 177.09M 13.29% | |
| EBIT YoY % growth | 1.307M 102.38% | 21.402M 1,537.49% | 56.291M 163.02% | 93.554M 66.20% | 105.34M 12.60% | 109.77M 4.21% | N/A | N/A | |
| Operating Margin | 0.26% | 3.73% | 9.91% | 15.33% | 16.19% | 15.81% | N/A | N/A | |
| EPS YoY % growth | 0.00 -100.00% | 0.47 | 0.68 44.68% | 0.78 14.86% | 0.89 13.36% | N/A | 1.05 | 1.21 15.38% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.10 30.45% | 0.23 10.62% | 0.20 31.30% | 0.25 3.10% | 0.14 35.49% | 0.28 21.74% | 0.20 2.56% | 0.30 22.45% |
| Revenue Q2Q % growth | 131.6M 6.24% | 160.11M 8.43% | 149.56M 7.87% | 169.83M 7.56% | 141.1M 7.22% | 169.07M 5.60% | 157.26M 5.15% | 176.65M 4.02% |
| EBITDA Q2Q % growth | 22.023M 30.97% | 32.846M -22.32% | 30.98M -33.47% | 36.589M -46.77% | 25.048M 13.74% | 38.683M 17.77% | 30.805M -0.56% | 40.4M 10.42% |
| EBIT Q2Q % growth | 14.893M 200.87% | 28.462M 54.95% | 28.919M 157.03% | 33.324M 53.42% | 22.018M 47.84% | 35.653M 25.27% | 27.775M -3.96% | 37.37M 12.14% |
All data in USD
8 analysts have analysed BVS and the average price target is 14.79 USD. This implies a price increase of 71.18% is expected in the next year compared to the current price of 8.64.
BIOVENTUS INC - A (BVS) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of BIOVENTUS INC - A (BVS) is 0.1 USD and the consensus revenue estimate is 131.60M USD.
The number of analysts covering BIOVENTUS INC - A (BVS) is 8.